Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Phase 1, Open-Label Study of NB003 to Assess Safety, Tolerability, Pharmacokinetics and Efficacy in Patients With Advanced Malignancies

NCT04936178 is registered in ClinicalTrials.gov with Ningbo Newbay Technology Development Co., Ltd as lead sponsor.

NCT NCT04936178
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04936178 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Phase 1, Open-Label Study of NB003 to Assess Safety, Tolerability, Pharmacokinetics and Efficacy in Patients With Advanced Malignancies
Lead sponsor
Ningbo Newbay Technology Development Co., Ltd
Phase
Phase 1
Overall status
Completed
Start date
August 6, 2021
Completion date
August 1, 2025
Enrollment
258 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor